AI Drug Discovery Startup Raises $400M
AAAzzam · x · 2026-07-14
A post shares funding news for an AI drug discovery company: it has closed a $400 million Series C round led by Index Ventures, with participation from Kleiner Perkins, Sequoia, DimensionCap, and others.
The concurrent business signal is that the value of AI in drug discovery has shifted from "proof of concept" to "actual deployment." The original post emphasizes that this is no longer just a discussion of future visions, but a transition into the execution phase.
Related event: AI Drug Discovery Firm Chai Raises $400M(3 posts)→
More from Venture
- AI cycle is entering its 'late-stage crypto' phase, argues investor: minor labs fade, startups pivot to GPU inference clouds — beffjezos · 2026-10-27
- Bedrock Robotics Raises $600M Series C as Autonomous Excavators Do Paid Work on US Job Sites — davidpattersonx · 2026-10-27
- WSJ Op-Ed: For Anthropic Share Offering Investors, a 10% Extinction Chance May Be a 90% Portfolio Win — davidmanheim · 2026-10-27
- WSJ: for Anthropic investors, a 10% extinction chance may still be a 90% portfolio win — peterwildeford · 2026-10-27
- Survey: 63% of CIOs see cost-level AI returns at scale, up from 14% pre-production — BenBajarin · 2026-10-27
- Anthropic's S-1 shows more cash than Microsoft, Google, Apple, Amazon or Nvidia — beffjezos · 2026-10-27